Cantargia publishes half year report
Cantargia AB’s (”Cantargia”) half year for the period January until June 2017 is now available on the company’s web page www.cantargia.com/en/investors/Financial reports.Significant events in the second quarter During the second quarter Cantargia received preliminary patent approval, which will protect CAN04 both as a substance and specifically for treatment of various forms of cancer in both Europe and the United States. Cantargia also received patent approval in China for use of IL1RAP as target molecule for antibody-based therapy of acute lymphoblastic leukemia. CAN04 showed to have